Published in Gastroenterology on June 30, 2011
Early Serum Infliximab Levels in Severe Ulcerative Colitis. (EaSiFx) | NCT01971814
The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. Am J Gastroenterol (2015) 2.51
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther (2015) 2.10
Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. Dig Dis Sci (2014) 1.48
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44
Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut (2013) 1.37
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis (2013) 1.27
New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol (2013) 1.25
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol (2015) 1.20
Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) (2012) 1.08
Therapy with stem cells in inflammatory bowel disease. World J Gastroenterol (2014) 1.03
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis (2015) 0.99
Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis. Gastroenterol Res Pract (2013) 0.99
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol (2013) 0.94
Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol (2015) 0.93
Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol (2014) 0.91
Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. Clin Transl Gastroenterol (2012) 0.90
Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol (2014) 0.90
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol (2015) 0.88
Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol (2016) 0.87
Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol (N Y) (2012) 0.87
Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol (2014) 0.87
Mucosal healing and deep remission: what does it mean? World J Gastroenterol (2013) 0.87
Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol (2014) 0.86
Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol (2013) 0.86
Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.85
Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Mol Nutr Food Res (2016) 0.85
Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol (2015) 0.84
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis (2016) 0.84
Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One (2014) 0.83
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease. Dig Dis Sci (2014) 0.82
Clinical usefulness of endocytoscopy in the remission stage of ulcerative colitis: a pilot study. J Gastroenterol (2015) 0.82
Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol (2012) 0.82
Molecular patterns in human ulcerative colitis and correlation with response to infliximab. Inflamm Bowel Dis (2014) 0.82
Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study. Dig Dis Sci (2016) 0.81
Raman spectroscopy of endoscopic colonic biopsies from patients with ulcerative colitis to identify mucosal inflammation and healing. Biomed Opt Express (2016) 0.81
Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol (2012) 0.81
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
Colon capsule endoscopy: current status and future directions. World J Gastroenterol (2014) 0.81
Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterol (2013) 0.81
Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. World J Gastroenterol (2014) 0.80
Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report. J Med Case Rep (2015) 0.80
The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol (2016) 0.80
The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis (2015) 0.80
The current and future role of endomicroscopy in the management of inflammatory bowel disease. Ann Gastroenterol (2015) 0.80
Parameters of a severe disease course in ulcerative colitis. World J Gastroenterol (2014) 0.79
Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. J Crohns Colitis (2015) 0.79
Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse. Am J Gastroenterol (2015) 0.79
Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J (2016) 0.79
Beyond white light endoscopy: the role of optical biopsy in inflammatory bowel disease. World J Gastroenterol (2013) 0.79
Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. Aliment Pharmacol Ther (2014) 0.79
Recent trends in diagnostic techniques for inflammatory bowel disease. Korean J Intern Med (2015) 0.79
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. Mediators Inflamm (2013) 0.79
Loss of interleukin 33 expression in colonic crypts - a potential marker for disease remission in ulcerative colitis. Sci Rep (2016) 0.78
Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. Am J Gastroenterol (2015) 0.78
Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res (2016) 0.78
IBD in 2011: Advances in IBD management--towards a tailored approach. Nat Rev Gastroenterol Hepatol (2012) 0.78
Intestinal Dilation and Platelet:Albumin Ratio Are Predictors of Surgery in Stricturing Small Bowel Crohn's Disease. Clin Gastroenterol Hepatol (2016) 0.78
Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. Dig Dis Sci (2016) 0.78
Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.77
Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol (2016) 0.77
Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg (2016) 0.77
Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y) (2015) 0.77
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol (2016) 0.76
Histological healing after infliximab induction therapy in children with ulcerative colitis. World J Gastroenterol (2015) 0.76
Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Can J Gastroenterol Hepatol (2016) 0.76
CTLA-4 and MDR1 polymorphisms increase the risk for ulcerative colitis: A meta-analysis. World J Gastroenterol (2015) 0.76
"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol (2014) 0.76
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol (2016) 0.76
Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Dig Dis Sci (2016) 0.76
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. Immune Netw (2017) 0.75
Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration. Biomed Res Int (2014) 0.75
Ulcerative colitis: Paediatric ulcerative colitis--can we predict proctocolectomy? Nat Rev Gastroenterol Hepatol (2012) 0.75
Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. World J Gastroenterol (2016) 0.75
Golimumab in unresponsive ulcerative colitis. Biologics (2014) 0.75
Colon Capsule Endoscopy: Where Are We and Where Are We Going. Clin Endosc (2016) 0.75
Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg (2015) 0.75
Assessment of disease activity by fecal immunochemical test in ulcerative colitis. World J Gastroenterol (2016) 0.75
Narrow-band imaging with magnifying endoscopy for Peyer's patches is useful in predicting the recurrence of remissive patients with ulcerative colitis. Intest Res (2016) 0.75
In vivo detection of mucosal healing-involved histiocytes by confocal laser endomicroscopy. World J Gastroenterol (2012) 0.75
Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels. Endosc Int Open (2017) 0.75
CD4 T cells are required for both development and maintenance of disease in a new mouse model of reversible colitis. Mucosal Immunol (2015) 0.75
The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference? F1000Prime Rep (2013) 0.75
The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing. Intest Res (2016) 0.75
The role of colonoscopy in inflammatory bowel disease. Clin Endosc (2013) 0.75
Activation of TGF-β activated kinase 1 promotes colon mucosal pathogenesis in inflammatory bowel disease. Physiol Rep (2017) 0.75
Developing a novel risk-scoring system for predicting relapse in patients with ulcerative colitis: A prospective cohort study. Pak J Med Sci (2016) 0.75
Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y) (2014) 0.75
Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol (2016) 0.75
Histologic Normalization Occurs in Ulcerative Colitis and is Associated with Improved Clinical Outcomes. Clin Gastroenterol Hepatol (2017) 0.75
Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci (2017) 0.75
Integrated Analysis of Biopsies from Inflammatory Bowel Disease Patients Identifies SAA1 as a Link Between Mucosal Microbes with TH17 and TH22 Cells. Inflamm Bowel Dis (2017) 0.75
Emerging biologics in inflammatory bowel disease. J Gastroenterol (2016) 0.75
Crossover Subsets of CD4(+) T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn's Disease and Ulcerative Colitis. Dig Dis Sci (2017) 0.75
Incidence and clinical outcomes of intestinal Behçet's disease in Korea, 2011-2014: a nationwide population-based study. J Gastroenterol (2016) 0.75
Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med (2017) 0.75
Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol (2017) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med (2007) 4.99
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Crohn's disease. Lancet (2012) 4.42
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension (2009) 3.48
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
Ulcerative colitis. Lancet (2012) 3.38
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36